CGTX · Cognition Therapeutics Inc
Market Cap
$92.21M
Shares
95.09M
Volume · Oct 5
331.79K
Avg daily vol (3M)
652.9K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.94
Open$0.94
Day$0.92–0.97
52W close$0.60–1.95
Avg vol 30d400K
Short int7.7M · 8.1% float · 22.6d
Short vol47%
Last earningsMar 26, 2026
DataOct 2021–Oct 2026
Filing10-Q · Aug 7
Up next
filed Aug 7, 2026
call held Mar 20, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-35.3%
Trailing year
Short interest
8.1%
Latest settlement · 22.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
−6%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−4%
trailing
YTD return
−31%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 66 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.14% of float · ▼ -1.5% MoM · 22.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
66 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
+63%
Y/Y
Free cash flow
$-24.6M
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 66 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.14% of float · ▼ -1.5% MoM · 22.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
66 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 25%
Range high $2
vs 200-day avg -17%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| clinical programs (research and development) | $2.86M | three months ended June 30, 2026 filing | — |
| Manufacturing (research and development) | $246K | three months ended June 30, 2026 filing | — |
| Other expense (research and development) | $39K | three months ended June 30, 2026 filing | — |
| Personnel (research and development) | $1.89M | three months ended June 30, 2026 filing | — |
| Preclinical programs (research and development) | $64K | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGTX
this stock
Cognition Therapeutics Inc
|
$92.21M | -30.5% | — | — | 8.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGTX | 0.0% | -8.9% | -3.8% | -2.3% | -30.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.2% | -9.5% | -15.4% | -3.9% | -44.1% |